Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Access Programme for Mepolizumab in Severe Asthma
2015-001152-29Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mepolizumab in severe asthma and asthma, sponsored by GSK. Started Jun 2015; status: completed.
02
Drugs
mepolizumab
03
Conditions
severe asthmaasthma
Beyond the preview
Go deeper on 2015-001152-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001152-29.